MaxiPost-mortem
Executive Summary
Second Phase III trial of stroke therapy MaxiPost "showed no significant difference in the overall efficacy and safety or tolerability between MaxiPost and placebo," Bristol reports. The first trial similarly failed to show evidence of benefit (1"The Pink Sheet" Jan. 29, p. 22). "We are now in the process of analyzing the data a little further, and we are going to review our options after that"